Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Operating profit | $m | -122 | -183 | ||||||
| Net profit | $m | -10 | -19 | -10 | -5 | -84 | -105 | -153 | -116 |
| EPS reported | $ | -2.31 | -2.41 | ||||||
| Operating cashflow per share | $ | -1.93 | -1.73 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -1.94 | -1.73 | ||||||
| Free cash flow | $m | -88 | -124 | ||||||
| Net debt | $m | -335 | -917 | ||||||
| Book value equity | $m | 472 | 1,197 | ||||||
| Book value per share | $ | 10.35 | 16.72 | ||||||
| Number of shares | m | 45.61 | 71.59 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 2.93 | 5.43 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -15.64 | -52.46 | ||||||
| EV/EBITDA LTM | x | -12.70 | -32.17 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | -7.63% | -2.23% | ||||||
| FCF Yield | % | -6.40% | -1.91% | ||||||
| Quality | |||||||||
| ROE | % | -22.34% | -18.66% | ||||||
| ROIC | % | -25.76% | -15.26% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | -100.00% | 0.00% | ||||||
| Payout Ratio | % | - | - | ||||||
| FCF/Debt | x | -45.77 | -42.24 | ||||||
| Net Debt/EBITDA | x | 0.43 | 1.09 | ||||||
| EBIT/Net interest | x | - | - | ||||||
| Net debt/market cap | % | -24.24% | -14.12% | ||||||
| Net debt/Equity | x | -0.71 | -0.77 | ||||||
| Gross debt/equity | x | 0.00 | 0.00 | ||||||
ETFs that hold Oruka Therapeutics
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Invesco Dorsey Wright SmallCap Momentum ETF | DWAS | 4 | 1.62% |
| ALPS Medical Breakthroughs ETF | SBIO | 1 | 4.58% |
Funds with Oruka Therapeutics among their ten largest holdings, largest fund first.
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Invesco Dorsey Wright SmallCap Momentum ETF | DWAS | 4 | 1.62% |
| ALPS Medical Breakthroughs ETF | SBIO | 1 | 4.58% |
Funds with Oruka Therapeutics among their ten largest holdings, largest fund first.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free